ESMO News

FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

about 20 hours ago

Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment

4 days ago

Findings from the interim analysis of the DESTINY-Breast05 study

Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma

5 days ago

Patient Guide in Prostate Cancer Now Available in Vietnamese

6 days ago

ESMO would like to thank the Hanoi Oncology Hospital (HOH) for providing...

Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma

6 days ago

Findings from the phase II cohort of the RedirecTT-1 study

One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses

7 days ago

Findings from the ESCUDDO study

EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide

11 days ago

It is a generic and hybrid of Xtandi, which has been authorised...

FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma

11 days ago

Evidence for efficacy is based on the results from the MATTERHORN study

Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance

12 days ago

The ESMO Immuno-Oncology Congress 2025 will take place from 10–12 December in...

EMA Recommends Extension of Indications for Tafasitamab

12 days ago

New indication concerns a combination with lenalidomide and rituximab for the treatment...

Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package

13 days ago

Providing clear and evidence-based information to consumers on the health risks posed...

FDA Approves New Interchangeable Biosimilar to Pertuzumab

13 days ago

Approval is based on comparisons across a broad range of structural and...